In this issue:
De-escalated pertuzumab + trastuzumab ±weekly paclitaxel in HER2+, hormone receptor–, early breast cancer
Cost effectiveness of pertuzumab with trastuzumab in metastatic breast cancer
Adjuvant chemotherapy in ILC: use of 21-gene recurrence score
FDG-PET/CT vs. contrast-enhanced CT monitoring of metastatic breast cancer
Trends in surgery and adjuvant treatment for early-stage breast cancer
Ribociclib + letrozole in males with hormone receptor+, HER2– advanced breast cancer
Switch maintenance endocrine therapy + bevacizumab after bevacizumab-paclitaxel in oestrogen receptor+, HER2– breast cancer
Mortality after late breast cancer recurrence
Outcomes for ultralow-risk participants from the MINDACT trial
De-escalation of adjuvant endocrine therapy in oestrogen receptor-low+ breast cancer
Please login below to download this issue (PDF)